Chronic myelogenous leukemia.

[1]  M. Scholl,et al.  Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation , 2001, Bone Marrow Transplantation.

[2]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[3]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[4]  N. Kröger,et al.  Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients , 2001, Bone Marrow Transplantation.

[5]  B. Druker,et al.  Chronic myelogenous leukemia , 2001, Current opinion in oncology.

[6]  O. Witte,et al.  Consequences of BCR‐ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia , 2000, Stem cells.

[7]  M. Scholl,et al.  The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy , 2000, Bone Marrow Transplantation.

[8]  H. Kantarjian,et al.  Therapeutic choices in younger patients with chronic myelogenous leukemia , 2000, Cancer.

[9]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[10]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[11]  J. Klein,et al.  Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission , 2000 .

[12]  J Hermans,et al.  Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2000, Blood.

[13]  J. Spivak,et al.  Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497 , 2000 .

[14]  C. Craddock,et al.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia , 2000 .

[15]  B. Bolwell.  Is Bone Marrow Transplantation Appropriate in Older Patients , 2000 .

[16]  B. Druker,et al.  Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.

[17]  W. Siegert,et al.  Interferon- Before Allogeneic Bone Marrow Transplantation in Chronic Myelogenous Leukemia Does Not Affect Outcome Adversely, Provided It Is Discontinued at Least 90 Days Before the Procedure , 1999 .

[18]  S. Woolf,et al.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.

[19]  Z. Estrov,et al.  Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.

[20]  R. Champlin,et al.  Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. , 1999, Oncology.

[21]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[22]  M. Andreeff,et al.  Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[24]  Takato O. Yoshida,et al.  EFFECT OF MATCHING OF CLASS I HLA ALLELES ON CLINICAL OUTCOME AFTER TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FROM AN UNRELATED DONOR , 1998 .

[25]  M. Horowitz,et al.  Initial therapy for chronic myelogenous leukemia: playing the odds. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C Anasetti,et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. , 1998, The New England journal of medicine.

[27]  Z. Estrov,et al.  Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Kantarjian,et al.  Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. , 1998, Hematology/oncology clinics of North America.

[29]  C Chastang,et al.  Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.

[30]  R. Mertelsmann,et al.  Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity , 1997, Bone Marrow Transplantation.

[31]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. , 1997, Blood.

[32]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  E. Estey,et al.  Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia , 1997, Leukemia.

[34]  S. Rutella,et al.  Separation of chemotherapy plus G-CSF-mobilized peripheral blood mononuclear cells by counterflow centrifugal elutriation: in vitro characterization of two different CD34+ cell populations. , 1996, Bone marrow transplantation.

[35]  M. Horowitz,et al.  Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. , 1996, Bone marrow transplantation.

[36]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[37]  E. Copelan,et al.  Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. , 1996, Bone marrow transplantation.

[38]  M. Andreeff,et al.  Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. , 1995, Blood.

[39]  F. Appelbaum,et al.  Bone marrow transplantation for chronic myelogenous leukemia. , 1995, Seminars in oncology.

[40]  F. Appelbaum,et al.  Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. , 1995, Bone marrow transplantation.

[41]  S. Richards,et al.  UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.

[42]  A. Elmaagacli,et al.  Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. , 1995, Blood.

[43]  D. Blaise,et al.  Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). , 1995, Blood.

[44]  H. Kantarjian,et al.  Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy , 1995, Annals of Internal Medicine.

[45]  G. Specchia,et al.  Ph positive acute lymphoblastic leukemia in adults: molecular and clinical studies. , 1995, Leukemia & lymphoma.

[46]  H. Heimpel,et al.  Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. , 1994, Blood.

[47]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. , 1994, Blood.

[48]  J. Klein,et al.  HLA-B44-directed cytotoxic T cells associated with acute graft-versus-host disease following unrelated bone marrow transplantation. , 1994, Bone marrow transplantation.

[49]  P. Ljungman,et al.  A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. , 1994, Blood.

[50]  A. Rimm,et al.  Identical-Twin Bone Marrow Transplants for Leukemia , 1994, Annals of Internal Medicine.

[51]  G. Gahrton,et al.  Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. , 1993, Bone marrow transplantation.

[52]  V. Vitale,et al.  Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). , 1993, Bone marrow transplantation.

[53]  M. Horowitz,et al.  Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase , 1993 .

[54]  E. Thomas,et al.  Treatment of chronic myeloid leukemia by marrow transplantation [editorial; comment] [see comments] , 1993 .

[55]  L. Grochow.  Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. , 1993, Seminars in oncology.

[56]  H. Heimpel,et al.  Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. , 1993, Blood.

[57]  S. Seeber,et al.  Impact of interferon alpha‐induced cytogenetic improvement on survival in chronic myelogenous leukaemia , 1993, British journal of haematology.

[58]  P. Beatty,et al.  Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. , 1993, Blood.

[59]  H. Deeg,et al.  Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. , 1992, Blood.

[60]  J. Szer,et al.  Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. , 1992, Blood.

[61]  B. Kennedy.  The evolution of hydroxyurea therapy in chronic myelogenous leukemia. , 1992, Seminars in oncology.

[62]  R. Kurzrock,et al.  Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. , 1991, Annals of internal medicine.

[63]  G. Morgan,et al.  Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.

[64]  S. Yang,et al.  Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. , 1990, The New England journal of medicine.

[65]  S. Mackinnon,et al.  Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. , 1990, Experimental hematology.

[66]  P. Beatty,et al.  Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. , 1990, Blood.

[67]  S. Piantadosi,et al.  Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia , 1989 .

[68]  P. Beatty,et al.  The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. , 1989, Bone marrow transplantation.

[69]  J U Gutterman,et al.  The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.

[70]  J. Goldman,et al.  Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. , 1988, Blood.

[71]  D. Arthur,et al.  Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  H. Deeg,et al.  Marrow transplantation for the treatment of chronic myelogenous leukemia. , 1986, Annals of internal medicine.

[73]  Francisco Cervantes,et al.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia , 1984 .

[74]  R. Dinsmore,et al.  Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. , 1984, Blood.

[75]  A. Gratwohl,et al.  Bone marrow transplantation for chronic myeloid leukemia. , 1984, Seminars in hematology.

[76]  J. Goldman,et al.  Application of bone marrow transplantation in chronic granulocytic leukaemia. , 1983, Clinics in haematology.

[77]  J. Gutterman,et al.  Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. , 1983, Blood.

[78]  R. Storb,et al.  Allogeneic Bone‐Marrow Transplantation , 1983, Immunological reviews.

[79]  R. Gale,et al.  Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase , 1982 .

[80]  D. Catovsky,et al.  MARROW TRANSPLANTATION FOR PATIENTS IN THE CHRONIC PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIA , 1982, The Lancet.

[81]  P. Neiman,et al.  TREATMENT OF CHRONIC GRANULOCYTIC LEUKAEMIA IN CHRONIC PHASE BY ALLOGENEIC MARROW TRANSPLANTATION , 1982, The Lancet.

[82]  D. Arthur,et al.  SUCCESSFUL ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS IN THE ACCELERATED PHASE OF CHRONIC GRANULOCYTIC LEUKAEMIA , 1982, The Lancet.

[83]  J. Curtis,et al.  Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility. , 1982, Canadian Medical Association journal.

[84]  R. Storb,et al.  Allogeneic bone marrow transplantation for chronic granulocytic leukemia. , 1981, Experimental hematology.

[85]  R. Storb,et al.  Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. , 1979, The New England journal of medicine.

[86]  G. Sale,et al.  Treatment of chronic granulocytic leukemia by chemotherapy, total body irradiation and allogeneic bone marrow transplantation. , 1978, Experimental hematology.

[87]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[88]  B. Kennedy,et al.  Hydroxyurea therapy in chronic myelogenous leukemia , 1972, Cancer.

[89]  D. Lane.  Chronic myelocytic leukemia , 2021, Cancers in the Urban Environment.

[90]  C. Symons,et al.  Measurement of A.D.P.-induced platelet aggregation and A.D.P.-splitting enzymes in plasma. , 1966, Lancet.

[91]  G. Cartwright,et al.  Busulfan in the treatment of chronic myelocytic leukemia. The effect of long term intermittent therapy. , 1961, Blood.

[92]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .